转移性前列腺癌多西他赛化疗中68Ga-HBED-CC-PSMA PET/CT疗效评估的初步结果
本研究纳入7例转移性去势敏感前列腺癌(mCSPC)患者和16例转移性去势抵抗前列腺癌(mCRPC)患者,分别在多西他赛化疗前后行68Ga-PSMA PET/CT,分别用PERCIST(稍作修改)和RECIST1.1评估疗效。初步结果显示68Ga-PSMA PET可能是有前景的疗效评估方法,但患者数有限,差异未达统计学显著,需更大样本前瞻性研究证实。
要点
- mCSPC患者生化部分缓解6/7例(86%,95%CI 42%–99.6%)。
- mCRPC患者生化部分缓解6/16例(38%,95%CI 15%–65%)。
- 作者认为68Ga-PSMA PET可能是有前景的疗效评估方法,但差异未达统计学显著。
核心结论
- 初步结果提示68Ga-PSMA PET可能是mCSPC和mCRPC治疗疗效评估的有前景的方法。
- 数据提示对于不同转移部位,68Ga-PSMA PET在疗效评估中的表现可能优于传统CT方法,并可能有助于区分进展性疾病与治疗反应。
- 由于患者数量有限,本研究显示的差异未达统计学显著,明确需要并值得开展更大规模的前瞻性研究来证实68Ga-PSMA PET作为疗效评估影像生物标志物的价值。
研究设计与样本
- 7例mCSPC患者在接受6周期一线多西他赛化疗前后行68Ga-PSMA PET/CT。
- 16例mCRPC患者在接受3周期姑息性多西他赛化疗前后行68Ga-PSMA PET/CT。
- 分别在68Ga-PSMA PET和CT数据集上独立评估影像学治疗反应。
- 采用稍作修改的PERCIST评分系统按患者和按病灶评估68Ga-PSMA摄取(SUVmean)变化。
- CT疗效评估采用RECIST1.1标准,并将PET与CT的影像学反应与生化反应(BR)进行比较和相关性分析。
主要发现
- mCSPC患者中生化部分缓解6/7例(86%,95%CI 42%–99.6%)。
- mCSPC患者中生化反应与PET影像学反应的一致率高于与CT影像学反应的一致率(6/7 vs. 3/6例)。
- mCSPC患者中68Ga-PSMA PET与CT仅3例一致(50%,95%CI 12%–88%)。
- mCRPC患者中生化部分缓解6/16例(38%,95%CI 15%–65%)。
- mCRPC患者中生化反应与PET影像学反应的一致率为9/16例(56%),与CT影像学反应的一致率仅4/12例(33%);68Ga-PSMA PET与CT结果在7/12例(58%,95%CI 28%–85%)中相符。
关键数值与推荐
- 治疗反应定义为治疗后PET所有靶病灶均无PSMA摄取(完全缓解,CR)或SUVmean总和下降≥30%(部分缓解,PR)。
- 出现新发PET阳性病灶或SUVmean总和升高≥30%(进展性疾病,PD)判定为无反应。
- SUVmean总和中度变化(-30%至+30%)且靶病灶数量无变化定义为疾病稳定(SD)。
- 血清PSA水平下降≥50%定义为生化部分缓解。
临床怎么用
- 原文未据此给出推荐。
- 作者认为68Ga-PSMA PET可能是mCSPC和mCRPC治疗疗效评估的有前景的方法。
局限性
- 患者数量有限,本研究显示的差异未达统计学显著。
- 明确需要并值得开展更大规模的前瞻性研究来证实68Ga-PSMA PET作为疗效评估影像生物标志物的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the value of 68Ga-HBED-CC PSMA (68Ga-PSMA) PET/CT for response assessment in metastatic castration-sensitive and castration-resistant prostate cancer (mCSPC and mCRPC) during docetaxel chemotherapy. METHODS: 68Ga-PSMA PET/CT was performed in seven mCSPC patients before and after six cycles of upfront docetaxel chemotherapy and in 16 mCRPC patients before and after three cycles of palliative docetaxel chemotherapy. Radiographic treatment response was evaluated separately on the 68Ga-PSMA PET and CT datasets. Changes in 68Ga-PSMA uptake (SUVmean) were assessed on a per-patient and a per-lesion basis using the PERCIST scoring system with slight modification. Treatment response was defined as absence of any PSMA uptake in all target lesions on posttreatment PET (complete response, CR) or a decrease in summed SUVmean of ≥30% (partial response, PR). The appearance of a new PET-positive lesion or an increase in summed SUVmean of ≥30% (progressive disease, PD) indicated nonresponse. A moderate change in summed SUVmean (between -30% and +30%) without a change in the number of target lesions was defined as stable disease (SD). For treatment response assessment on CT, RECIST1.1 criteria were used. Radiographic responses on 68Ga-PSMA PET [RR(PET)] and on CT [RR(CT)] were compared and correlated with biochemical response (BR). A decrease in serum PSA level of ≥50% was defined as biochemical PR. RESULTS: Biochemical PR was found in six of seven patients with mCSPC (86%, 95% confidence interval 42% to 99.6%). The concordance rate was higher between BR and RR(PET) than between BR and RR(CT) (6/7 vs. 3/6 patients. 68Ga-PSMA PET and CT were concordant in only three patients (50%, 12% to 88%). In mCRPC patients, biochemical PR was found in six of 16 patients (38%, 15% to 65%). Outcome prediction was concordant between BR and RR(PET) in nine of 16 patients (56%), and between BR and RR(CT) in only four of 12 patients (33%) with target lesions on CT. 68Ga-PSMA PET and CT results corresponded in seven of 12 patients (58%, 28% to 85%). CONCLUSION: Our preliminary results suggest that 68Ga-PSMA PET might be a promising method for treatment response assessment in mCSPC and mCRPC. The data indicate that for different metastatic sites, the performance of 68Ga-PSMA PET in response assessment might be superior to that of the conventional CT approach and could help differentiate between progressive disease and treatment response. Because of the limited number of patients, the differences revealed in our study were not statistically significant. Thus larger and prospective studies are clearly needed and warranted to confirm the value of 68Ga-PSMA PET as an imaging biomarker for response assessment.
引用
- Seitz AK, Rauscher I, Haller B, et al. Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2017. PMID: 29185010. doi:10.1007/s00259-017-3887-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。